Impax Laboratories Inc

Impax Laboratories — J.P. Morgan Healthcare Conference 2012

22 slides from Impax Laboratories's conference presentation, Jan 9, 2012

  1. Slide 1: Improving Health Through Technology

    Slide 1: Improving Health Through Technology

    ....Improving Health Through Technology J.P. Morgan Healthcare Conference January 9, 2012 Larry Hsu - President & CEO Art Koch - Chief Financial Officer

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of ma

  3. Slide 3: Impax's Dual Strategic Focus

    Slide 3: Impax's Dual Strategic Focus

    3 Impax's Dual Strategic Focus Unique targeted ANDAs First-to-File, First-to-Market Sustainability through limited competition Difficult to formulate and manufacture 47 apps pending at FDA 46 under development Improve on marketed CNS products Develop IP positions IPX066 NDA filed 4Q11 as 505(b)(2) f

  4. Slide 4: Update on Quality Improvements

    Slide 4: Update on Quality Improvements

    Quality Improvements Responded to all warning letter observations Upgraded quality and operations management teams Implemented global Quality Improvement Program Continue to update and communicate with FDA Goal to close out warning letter by end of February 2012 Timing dependent on FDA availability

  5. Slide 5: A Leader in Generic Medicines

    Slide 5: A Leader in Generic Medicines

    ....A Leader in Generic Medicines

  6. Slide 6: Generic Growth Initiatives

    Slide 6: Generic Growth Initiatives

    6 Generic Growth Initiatives

  7. Slide 7: Growing Partnership Portfolio

    Slide 7: Growing Partnership Portfolio

    Growing Partnership Portfolio 7 Supply and commercialization agreement 2 softgel capsule products Development and commercialization agreement 1 nasal spray product 1 topical product Development and supply agreement 2 topical drug products Focusing on Alternative Dosage Forms ....and additional undis

  8. Slide 8: Expanding ANDA Pending Pipeline

    Slide 8: Expanding ANDA Pending Pipeline

    8 Expanding ANDA Pending Pipeline 2011 ANDA Filing Goal At least 12 new ANDA applications At least 3 First-to-File or First-to-Market opportunities Results to Date 2008 2009 2010 2011E Non FTF/FTM 6 7 9 7 Potential FTM 2 Potential Shared FTF 2 Potential FTF 2 3 1 1 10 10 10 10(a) (a) Does not reflec

  9. Slide 9: Products Pending or Under Development

    Slide 9: Products Pending or Under Development

    9 93 Products Pending or Under Development 44 Currently Marketed ANDAs 46 Under Development ($15 Billion) 47 Pending at FDA ($20 Billion) Present Future Opportunities $35 Billion U.S. Brand/Generic Sales Note: All product sales data included herein are derived from data published by Wolters Kluwer H

  10. Slide 10: Disclosed ANDA Pending Pipeline Offers Growth Opportunities

    Slide 10: Disclosed ANDA Pending Pipeline Offers Growth Opportunities

    10 Disclosed ANDA Pending Pipeline Offers Growth Opportunities Disclosed ANDA Pending Pipeline Offers Growth Opportunities Disclosed ANDA Pending Pipeline Offers Growth Opportunities Impax is aware of additional lawsuits containing similar patent infringement claims and believes filers of ANDAs will

  11. Slide 11: Under Development Pipeline

    Slide 11: Under Development Pipeline

    11 Under Development Pipeline Total Under Development 46 $15B * Brands not yet launched or sales data not yet available Unique Targeted High Value ANDAs First-to-File/First-to-Market First-to-File/First-to-Market First-to-File/First-to-Market Focused on: Note: All product sales data included herein

  12. Slide 12: Advancing CNS Treatment

    Slide 12: Advancing CNS Treatment

    ....Advancing CNS Treatment

  13. Slide 13: Brand Growth Initiatives

    Slide 13: Brand Growth Initiatives

    Brand Growth Initiatives Terma R&D Programs | Collaborations in Pipeline Development & Commercialization Approval and Launch of IPX066 in U.S. In-licensing (products) “Driving to Financial Self-Support” @ MEAN

  14. Slide 14: Phase III Results Support Potential Benefits for Parkinson's Disease Patients

    Slide 14: Phase III Results Support Potential Benefits for Parkinson's Disease Patients

    14 Phase III Results Support Potential Benefits for Parkinson's Disease Patients Reduced "Off" time Reduced dosing frequency Increased patient Preference for Treatment Increased "On" time IPX066: Controlled-release Carbidopa/Levodopa IPX066 Improved Motor Symptoms "Data on file, Impax Laboratories"

  15. Slide 15: IPX066: Next Steps in 2012

    Slide 15: IPX066: Next Steps in 2012

    15 IPX066: Next Steps in 2012 Dec. 2011 Feb./Mar -2012 4Q 2012 Throughout 2012 NDA filed Pre-launch preparation and launch planning Building marketing and sales team Conducting commercial pre-launch activities Expected FDA acceptance of NDA Possible NDA approval

  16. Slide 16: Clinical Stage Pipeline - IPX159

    Slide 16: Clinical Stage Pipeline - IPX159

    16 Clinical Stage Pipeline - IPX159 IPX159 - Restless Legs Syndrome (RLS) IPX159 Development Overview Product Overview Ex-US compound, NCE US Inhibits uptake of neurotransmitters RLS Market Opportunity US registration path 505(b)(1) - 5 year regulatory exclusivity Significant Commercial Opportunity

  17. Slide 17: IPX159: Development Status

    Slide 17: IPX159: Development Status

    17 IPX159: Development Status Preclinical & POC Phase I Phase IIa Phase IIb - Initiated December 2011 Completed Completed Completed Primary endpoint: International Restless Legs Syndrome Study Group (IRLSSG) Rating Scale Safety and efficacy study North America, randomized, double- blind, placebo-con

  18. Slide 18: 2012 Financial Outlook

    Slide 18: 2012 Financial Outlook

    2012 Financial Outlook ....Improving Health Through Technology

  19. Slide 19: Healthy Balance Sheet Supports Ongoing M&A

    Slide 19: Healthy Balance Sheet Supports Ongoing M&A

    Healthy Balance Sheet Supports Ongoing M&A 19 Significant cash and no debt for investments in growth initiatives

  20. Slide 20: 2012 Financial Outlook

    Slide 20: 2012 Financial Outlook

    20 2012 Financial Outlook Top-line performance driven generic division products: Variability depending on Generic Adderall XR(r) Supply issues and Shire litigation Citizen Petition status Resolution of warning letter Potential launch of eight generic products Gross margins expected in ~ 47% to 49% r

  21. Slide 21: 2012 Financial Outlook

    Slide 21: 2012 Financial Outlook

    21 2012 Financial Outlook 2012 Financial Outlook

  22. Slide 22: Strong Platform for Long Term Growth

    Slide 22: Strong Platform for Long Term Growth

    22 22 Strong Platform for Long Term Growth Unique Targeted High Value ANDAs Offering Long-Term Growth Drivers Generic Brand Drug Delivery Expertise Product Development Formulation Technology Core Competency

Source: SEC EDGAR · 8-K filed Jan 9, 2012

More decks from Impax Laboratories Inc